WO2017115252A1 - An oral osmotic pharmaceutical composition of vildagliptin - Google Patents

An oral osmotic pharmaceutical composition of vildagliptin Download PDF

Info

Publication number
WO2017115252A1
WO2017115252A1 PCT/IB2016/057975 IB2016057975W WO2017115252A1 WO 2017115252 A1 WO2017115252 A1 WO 2017115252A1 IB 2016057975 W IB2016057975 W IB 2016057975W WO 2017115252 A1 WO2017115252 A1 WO 2017115252A1
Authority
WO
WIPO (PCT)
Prior art keywords
vildagliptin
salt
hours
composition
released
Prior art date
Application number
PCT/IB2016/057975
Other languages
English (en)
French (fr)
Inventor
Mandar Madhukar KODGULE
Amit Bansal
Ganesh SANGLE
Kapileshwar SWAIN
Nitin Saigal
Sanjay Gaikwad
Sunil Kumar AGARWAL
Original Assignee
Wockhardt Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wockhardt Limited filed Critical Wockhardt Limited
Priority to KR1020187016451A priority Critical patent/KR20180092981A/ko
Priority to MX2018007681A priority patent/MX2018007681A/es
Priority to RU2018120202A priority patent/RU2706706C1/ru
Priority to BR112018013195A priority patent/BR112018013195A2/pt
Publication of WO2017115252A1 publication Critical patent/WO2017115252A1/en
Priority to PH12018550075A priority patent/PH12018550075A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • the invention relates to a novel osmotic pharmaceutical composition comprising vildagliptin or salt thereof.
  • the invention further provides a process of preparing such compositions.
  • Diabetes mellitus is a common disorder more prevalent in developed countries. It is characterized by its clinical manifestations, namely the non-insulin-dependent or maturity onset form, also known as type 2 diabetes and the insulin-dependent or juvenile onset form, also known as type 1 diabetes. It is a metabolic disease in which there is a high blood sugar level over a prolonged period. This disorder is associated with high morbidity and mortality.
  • Dipeptidyl-peptidase-IV (DPP-IV) inhibitors are an oral drug class that was introduced in 2006 and that seems easy to use and do not require regular glucose monitoring or dose adjustments.
  • DPP-IV inhibitors act by inhibiting DPP-IV enzyme, a multifunctional transmembrane glycoprotein enzyme that cleaves N-terminal dipeptides from polypeptides with L-proline or L- alanine at the penultimate position.
  • Vildagliptin is an orally active inhibitor of the DPP-IV enzyme.
  • insulinotropic hormone glucagon- like peptide- 1 GLP-1
  • Some of the GLP-1 is inactivated by the DPP-IV present in plasma and intestinal capillary endothelium. Therefore, if the DPP-IV inhibited, more GLP-1 will be available to activate insulin release from the pancreas.
  • U.S. Patent No. 6,166,063 discloses a DPP-IV inhibitor compound vildagliptin, its use in treating type-2 diabetes mellitus and its pharmaceutical composition.
  • U.S. Patent No. 6,303,661 discloses methods of using an oral inhibitor of DPP-IV or DPP IV-like enzyme activity to reduce blood glucose levels after food intake.
  • U.S. Patent No. 8,143,217 discloses methods of using vildagliptin in combination with insulin to treat hypoglycemic events in a patient with diabetes.
  • European Patent Application, EP 1,537,880 Al relates to a sustained release formulation of DPP-IV inhibitor (Vildagliptin) comprising a hydrophilic polymer.
  • EP 2,191,824 Bl discloses sustained release formulation of DPP-IV inhibitor (Vildagliptin) comprising hydroxypropyl methylcellulose.
  • DPP-IV inhibitor Vildagliptin
  • European Patent Application, EP 2,578,208 Al discloses solid dosage formulation obtained with briquette pressing or compression between rollers and characterized in that it comprises DPP-IV inhibitor.
  • PCT Publication No. WO 2014/029841 Al discloses extended release compositions of an amino-C2-C6-alkyl nitrate and fixed dose combinations with vildagliptin.
  • the existing vildagliptin product is a direct compression tablet with a 25% drug load.
  • Patient adherence to a drug regimen indirectly correlates with frequency of dosing i.e. greater adherence is seen with a once daily dosing regimen compared to a twice daily dosing regimen.
  • the majority of data currently available for vildagliptin is derived from studies based on the immediate release formulation (GALVUS ) having twice daily dosing regimen. There is a need to provide a once a daily formulation of vildagliptin which will provide ease, convenience and reduced side effects profile.
  • a general aspect of the invention discloses an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type
  • the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C and/or about 85%
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5;
  • a seal coat surrounding the core comprising a sustained release coat cellulose acetate surrounding the seal coat;
  • an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vilda
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising about 70% to about 95% by weight cellulose acetate, and
  • step (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • Figure 1A and Figure IB shows in- vitro dissolution profile of vildagliptin composition 1A and composition IB respectively, at acid stage and buffer stage.
  • Figure 2 A shows % DPP-IV inhibition after administration of invention composition 1A and GALVUS ® .
  • Figure 2B shows Plasma-drug concentration profile after administration of invention composition 1A and GALVUS ® .
  • Figure 3 A shows % DPP-IV inhibition after administration of invention composition IB and GALVUS ® .
  • Figure 3B shows Plasma-drug concentration profile after administration of invention composition IB and GALVUS ® .
  • Figure 4 shows in- vitro dissolution profile of comparative vildagliptin composition 6A and 6B at acid stage and buffer stage.
  • a general aspect of the invention discloses an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • osmotic pharmaceutical composition refers to an advanced controlled release solid drug delivery system with a sustained release coat and one or more small laser drilled bores in it.
  • core refers to a matrix or a bilayer or a trilayer or a multilayer component having a drug, osmotic agent and one or more pharmaceutically acceptable excipients.
  • sustained release coat refers to a semi-permeable membrane controlling drug release.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type
  • the composition exhibits an in-vitro release profile such that about 15% to about 25% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 18% to about 22% of vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 20% of vildagliptin or salt thereof is released at 2 hours when measured in 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 80% to about 90% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 85% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 25% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 25% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 90% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 90% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 10 ng/ml to about 200 ng/ml, or about 20 ng/ml to about 150 ng/ml, or about 30 ng/ml to about 100 ng/ml, or about 40 ng/ml to about 50 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 10 ng/ml to about 20 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. Alternatively, the composition can decrease DPP-IV enzyme activity in blood plasma by about 70% to about 80% over the period of 24 hours. Alternatively, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 20 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 18 hours.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 16 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 14 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 12 hours. In another embodiment, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 10 hours.
  • the core comprises a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof.
  • the drug layer comprises about 45 mg to about 90 mg, or about 55 mg to about 85 mg, or about 65 mg to about 75 mg of vildagliptin or salt thereof.
  • the drug layer comprises about 40 mg, or about 45 mg, or about 50 mg, or about 55 mg, or about 60 mg, or about 65 mg, or about 70 mg, or about 75 mg, or about 80 mg, or about 85 mg, or about 90 mg of vildagliptin or salt thereof.
  • the drug layer comprises about 75 mg of vildagliptin or salt thereof.
  • the drug layer further comprises pharmaceutically acceptable excipients such as swelling polymer like polyethylene oxide having molecular weight of about 100,000 to 200,000, osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the preferred osmotic agent is mannitol and lubricants like magnesium stearate, zinc stearate, sodium stearyl fumarate.
  • the drug layer comprises polyethylene oxide having molecular weight of about 100,000 to 200,000 is present in about 170 mg to about 200 mg, or about 188 mg or about 190 mg or about 195 mg.
  • the drug layer comprises osmotic agent that is mannitol present in about 30 mg to about 50 mg or about 36 mg.
  • the core comprises the push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000.
  • the push layer comprises polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 and is present in about 70 mg to about 100 mg, or about 80 mg to about 90 mg.
  • the push layer comprises polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 and is present in about 85 mg, or 90 mg or 95 mg.
  • the push layer further comprises pharmaceutically acceptable excipients such osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • osmotic agents selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the preferred osmotic agent is sodium chloride, binder such as hydroxypropyl methylcellulose (HPMC) having viscosity of 3cP to 6cP when present in 2% solution, and lubricants like magnesium stearate, zinc stearate, sodium stearyl fumarate.
  • HPMC hydroxypropyl methylcellulose
  • the push layer comprises osmotic agent that is sodium chloride present in about 30 mg to about 50 mg or about 45 mg.
  • the osmotic agent present in drug layer is different than push layer.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core ranges from about 1 :1 to about 1 :10. In another embodiment, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core ranges from about 1 :1 to about 1 :3. Alternatively, the weight ratio of vildagliptin or salt thereof and polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000 in the core is about 1 :1.10, or about 1 :1.15, or about 1 :1.20, or about 1 :1.25.
  • the core is surrounded by a seal coat selected from commercially available coating system such as Opadry®.
  • the seal coat is surrounded by a sustained release coat comprising about 80% to about 90% by weight cellulose acetate.
  • the seal coat is surrounded by a sustained release coat comprising about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • the sustained release coat is surrounded by an immediate release drug layer comprising about 20 mg to about 30 mg of vildagliptin or salt thereof, or about 25 mg of vildagliptin or salt thereof.
  • the total amount of vildagliptin or salt thereof present in composition is about 100 mg or about 150 mg or about 200 mg or about 250 mg or about 300 mg, wherein about 90%, or about 80%, or about 70% or about 60% or about 50% of vildagliptin or salt thereof is present in the core of composition and about 10%, or about 20%, or about 30%, or about 40%, or about 50% of vildagliptin or salt thereof is present in the immediate release drug layer.
  • compositions are present in the form of an oral formulation such as a tablet, capsule (including a microcapsule), granule, or powder; of these forms, an oral formulation such as a tablet is preferred.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • a core comprising: (i) a drug
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 95 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 85 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C. In one embodiment of this aspect, about 15%
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C. In one embodiment of this aspect, about 15%
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C. In another embodiment of this aspect, about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the osmotic agent present in drug layer is different than push layer.
  • the sustained release coat comprises about 40 mg cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • kits comprising an osmotic pharmaceutical composition
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the core comprises about 75 mg of vildagliptin or salt thereof.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the sustained release coat comprises about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 : 1 to about 1 :5;
  • a seal coat surrounding the core comprising a sustained release coat cellulose acetate surrounding the seal coat;
  • an immediate release drug layer comprising vildagliptin or salt thereof surrounding the sustained release coat.
  • a method of treating type 2 diabetes comprises administering to a patient in a need thereof an osmotic pharmaceutical composition
  • a core comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 10% to about 30% of
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in-vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration.
  • the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the core comprises about 75 mg of vildagliptin or salt thereof.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the sustained release coat comprises about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 35 mg to about 95 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000, wherein weight ratio of vildagliptin or salt thereof and polyethylene oxide ranges from about 1 :1 to about 1 :5; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 70% to about 95% by weight cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 15 mg to about 35 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in- vitro release profile such that about 10% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising about 70% to about 95% by weight cellulose acetate, and
  • step (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • vildagliptin or salt thereof is released at 2 hours when measured in 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition exhibits an in- vitro release profile such that about 70% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours when measured in phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period of 3 months at about 30°C/65% relative humidity and exhibits an in- vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0. IN HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HC1 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 30°C/65% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition is storage stable for a period 3 months at 40°C/75% relative humidity and exhibits an in-vitro release profile such that about 85% to about 95% of vildagliptin or salt thereof is released at 24 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, phosphate buffer of pH 6.8 at 37°C ⁇ 0.5°C.
  • the composition provides a mean plasma concentration of vildagliptin or salt thereof in the range of about 5 ng/ml to about 250 ng/ml over a period of at least 24 hours after once daily oral administration. In another embodiment of this aspect, the composition provides a mean plasma concentration of vildagliptin or salt thereof of about 5 ng/ml to about 30 ng/ml at 24 hours after once daily oral administration. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 60% to about 90% over the period of 24 hours. In another embodiment of this aspect, the composition can decrease DPP-IV enzyme activity in blood plasma by about 80% over the period of 24 hours.
  • the core comprises about 75 mg of vildagliptin or salt thereof.
  • the weight ratio of vildagliptin or salt thereof and polyethylene oxide in the core ranges from about 1 :1 to about 1 :3.
  • the push layer further comprises hydroxypropyl methylcellulose in an about 3% to about 7% by weight.
  • the core further comprises at least one osmotic agent selected from the group consisting of sucrose, xylitol, glucose, lactose, mannitol, sodium chloride, potassium chloride, cellulose ethers, maltodextrins, and cyclodextrins.
  • the sustained release coat comprises about 90% by weight cellulose acetate.
  • the sustained release coat includes at least one bore suitable for providing the osmotic delivery of the vildagliptin or salt thereof from the core, wherein said bore has cross section of about 0.1 to about 1 mm 2 or about 0.7 mm 2 .
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 80 mg to about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising cellulose acetate, and (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • an osmotic pharmaceutical composition comprising: (a) a core, comprising: (i) a drug layer comprising about 75 mg of vildagliptin or salt thereof, and one or more pharmaceutically acceptable excipients; (ii) a push layer comprising about 90 mg of polyethylene oxide having molecular weight of about 5,000,000 to about 8,000,000; (b) a seal coat surrounding the core; (c) a sustained release coat comprising about 35 mg to about 45 mg of cellulose acetate surrounding the seal coat; (d) an immediate release drug layer comprising about 25 mg of vildagliptin or salt thereof surrounding the sustained release coat; and wherein the composition exhibits an in-vitro release profile such that about 20% to about 30% of vildagliptin or salt thereof is released at 2 hours, when measured in USP apparatus Type I, at 100 rpm using 900 ml, 0.1N HCl at 37°C ⁇ 0.5°C, and where
  • step (e) coating the seal coat of step (d) with the sustained release coat comprising cellulose acetate
  • step (f) coating the sustained release coat of step (e) with the immediate release drug layer comprising vildagliptin or salt thereof to obtain the osmotic pharmaceutical composition.
  • EXAMPLE 1 Osmotic compositions of vildagliptin Total Tab. wt. 504.19 504.19
  • Step II Separately passed mannitol thorough #40 sieve and geometrically blended with Step I mixture.
  • Step II powder blend was granulated with IPA in a rapid mixer granulator by spraying
  • Iron Oxide passed thorough #60 mesh mixed with the step I mixture for 5 minutes.
  • Step II powder blend was granulated with IPA in a rapid mixer granulator by spraying
  • SPM Semi-Permeable membrane
  • step II Seal coated tablets were coated with step I solution until a weight gain of 10% w/w is attained.
  • Opadry solution was added to the drug solution under stirring and mixed for 30 minutes.
  • the drug layer side of the above tablet was drilled by with a 0.6 mm needle using a tablet laser drilling machine.
  • Opadry 03K19229 (clear) was dispersed in IPA and stirred for 30 minutes. MDC was added to the above solution and mixed for 10 minutes.
  • EXAMPLE 2 Dissolution testing of osmotic pharmaceutical compositions of Example 1.
  • Diluent Use dissolution medium as diluent.
  • Diluent Use dissolution medium as diluent.
  • example 1 (1A and IB) compositions 100 mg
  • GALVUS® 50 mg
  • Percent inhibition of DPP-IV was calculated as 100 x (1 - A t /A 0 ), where A 0 was the enzyme activity measured predose and At was the activity measured post-dose at time t in the same treatment period. Plasma drug concentrations were measured using LC-MS method. The results obtained are presented in the form of mean ⁇ SEM in Fig 2A and Fig 2B for example 1A and Fig 3 A and Fig 3B for example IB composition.
  • GALVUS® showed >80% DPP-IV inhibition from 0.5 - 6 hour during first dose and 10.5-16 hour during second dose. Overall, GALVUS maintained >80 % DPP-IV inhibition for 6 hour after each dose. After 6 hour of administration, GALVUS showed DPP-IV inhibition below 80% which correlates with plasma drug concentration.
  • Example 1A composition reported >80% DPP-IV inhibition up to 14 hours which is in alignment with plasma drug concentrations. The drop in DPP-IV inhibition after 20 hours may be attributed to incomplete drug release. Example 1A composition showed consistent and longer DPP-IV inhibition compared with GALVUS®.
  • example IB composition showed > 80% DPP-IV inhibition up to 8 hour and more than 70% up to 14 hour.
  • DPP-IV activity correlated with plasma drug concentrations and in-vitro results. Relative Bioavailability of 95% achieved against GALVUS .
  • the similar and consistent PK/PD outcomes can be anticipated in human volunteers in view of drug half-life and clearance correlations between humans and dogs.
  • composition Example IB Tablets of composition Example IB were packed in Alu Alu blisters and were loaded on stability under the 40°C ⁇ 2°C & 75%RH ⁇ 5%RH and 30°C ⁇ 2°C & 65%RH ⁇ 5%RH and evaluated for assay, dissolution and impurity profile.
  • the invention composition (example IB) remain storage stable at 40°C ⁇ 2°C & 75%RH ⁇ 5%RH and 30°C ⁇ 2°C & 65%RH ⁇ 5%RH conditions.
  • the compositions were also proved to dissolution stable at these conditions.
  • EXAMPLE 5 Osmotic compositions of vildagliptin
  • Example 5 The compositions of Example 5 were prepared by the process as described in Example 1.
  • EXAMPLE 6 Comparative examples
  • the comparative example compositions of Example 6 were prepared by the process described in Example 1.
  • the comparative example compositions 6A and 6B were subjected to in- vitro dissolution testing at the condition provided in example 2 and compared with invention composition 1A.
  • Figure 4 shows in- vitro dissolution profile of comparative vildagliptin composition 6A and 6B at acid stage and buffer stage and following table points out the difference between invention composition and comparative examples:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IB2016/057975 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin WO2017115252A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020187016451A KR20180092981A (ko) 2015-12-28 2016-12-23 빌다글립틴의 경구 삼투압성 약제학적 조성물
MX2018007681A MX2018007681A (es) 2015-12-28 2016-12-23 Composicion farmaceutica osmotica oral de vildagliptin.
RU2018120202A RU2706706C1 (ru) 2015-12-28 2016-12-23 Пероральная осмотическая фармацевтическая композиция вилдаглиптина
BR112018013195A BR112018013195A2 (pt) 2015-12-28 2016-12-23 composição farmacêutica osmótica oral de vildagliptina
PH12018550075A PH12018550075A1 (en) 2015-12-28 2018-06-01 An oral osmotic pharmaceutical composition of vildagliptin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN4891MU2015 2015-12-28
IN4891/MUM/2015 2015-12-28

Publications (1)

Publication Number Publication Date
WO2017115252A1 true WO2017115252A1 (en) 2017-07-06

Family

ID=57966046

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2016/057975 WO2017115252A1 (en) 2015-12-28 2016-12-23 An oral osmotic pharmaceutical composition of vildagliptin

Country Status (6)

Country Link
KR (1) KR20180092981A (pt)
BR (1) BR112018013195A2 (pt)
MX (1) MX2018007681A (pt)
PH (1) PH12018550075A1 (pt)
RU (1) RU2706706C1 (pt)
WO (1) WO2017115252A1 (pt)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6166063A (en) 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US6303661B1 (en) 1996-04-25 2001-10-16 Probiodrug Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
EP1537880A1 (en) 2002-09-11 2005-06-08 Takeda Pharmaceutical Company Limited Sustained release preparation
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2191824A1 (en) * 2005-06-10 2010-06-02 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US8143217B2 (en) 2005-09-20 2012-03-27 Novartis Ag Use of DPP-IV inhibitor to reduce hypoglycemic events
EP2578208A1 (en) 2011-10-06 2013-04-10 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303661B1 (en) 1996-04-25 2001-10-16 Probiodrug Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
US6166063A (en) 1998-12-10 2000-12-26 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1537880A1 (en) 2002-09-11 2005-06-08 Takeda Pharmaceutical Company Limited Sustained release preparation
EP2191824A1 (en) * 2005-06-10 2010-06-02 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
EP2191824B1 (en) 2005-06-10 2012-03-14 Novartis AG Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
US8143217B2 (en) 2005-09-20 2012-03-27 Novartis Ag Use of DPP-IV inhibitor to reduce hypoglycemic events
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
WO2009111200A1 (en) * 2008-03-04 2009-09-11 Merck & Co., Inc. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
EP2578208A1 (en) 2011-10-06 2013-04-10 Sanovel Ilac Sanayi ve Ticaret A.S. DPP-IV inhibitor solid dosage formulations
WO2014029841A1 (en) 2012-08-23 2014-02-27 Cardiolynx Ag Extended release compositions of an aminoalkyl nitrate

Also Published As

Publication number Publication date
BR112018013195A2 (pt) 2018-12-11
PH12018550075A1 (en) 2019-01-28
RU2706706C1 (ru) 2019-11-20
KR20180092981A (ko) 2018-08-20
MX2018007681A (es) 2018-11-14

Similar Documents

Publication Publication Date Title
TWI483943B (zh) 醫藥組合物、醫藥劑型、其製備方法及其用途
EP2217205B1 (en) Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
CN101277688B (zh) 包含甲福明和维达列汀的配制物
JP4474162B2 (ja) Ｉｉ型糖尿病の治療に用いられる医薬組成物
EP2590631B1 (en) Formulation for co-therapy treatment of diabetes
EP2210595A1 (en) Active coating of pharmaceutical dosage forms
US20060141023A1 (en) Pharmaceutical compositions containing abiguanide-glitazone combination
KR20140007247A (ko) 음식물 영향이 감소된 제어 방출 조성물
JP2013508370A (ja) ジペプチジルペプチダーゼ−４阻害剤とピオグリタゾンとの組み合わせの医薬組成物
EP4114365A1 (en) Pharmaceutical composition comprising sglt2 inhibitor
WO2014170770A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
WO2016016770A1 (en) A novel modified release pharmaceutical composition of sitagliptin or pharmaceutically acceptable salt thereof
WO2021076066A1 (en) Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
WO2016016772A1 (en) A novel modified release pharmaceutical composition of dpp-iv inhibitors or pharmaceutically acceptable salt thereof
CN103251593B (zh) 瑞格列奈二甲双胍组合物
KR100774774B1 (ko) 메트포르민 서방성 제제 및 그 제조방법
WO2014167437A1 (en) Solid oral pharmaceutical compositions comprising fixed dose combination of metformin and sitagliptin or salts thereof
HU231052B1 (hu) Bisoprololt és ramiprilt tartalmazó stabil kombinációs gyógyszerkészítmény
WO2017115252A1 (en) An oral osmotic pharmaceutical composition of vildagliptin
KR102362342B1 (ko) 빌다글립틴 및 메트포민 포함하는 복합 정제
WO2023012817A1 (en) A pharmaceutical composition comprising combination of dapagliflozin and sitagliptin
EP4376807A1 (en) A pharmaceutical composition comprising combination of sglt2 inhibitor and dpp-iv inhibitor
Vijay et al. Formulation and Evaluation of Bilayer Tablet Containing Metoprolol Layer as A Sustain Release Part & Ramipril Layer as an Immediate Release Part
WO2004082591A2 (en) Pharmaceutical composition for treatment of diabetes mellitus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16834195

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 12018550075

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20187016451

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2018/007681

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112018013195

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2018120202

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 112018013195

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20180626

122 Ep: pct application non-entry in european phase

Ref document number: 16834195

Country of ref document: EP

Kind code of ref document: A1